

## Location

Pullman Basel Europe Hotel,  
Clarastrasse 43, 4058 Basel

## Registration



[unispital-basel.ch/ueber-uns/innovationsfocus/innovations-focus-zelltherapien](https://unispital-basel.ch/ueber-uns/innovationsfocus/innovations-focus-zelltherapien)

Attendance of this symposium is accredited as continuous medical education for specialists in infectious diseases, in medical oncology and in hematology.

**Credits:** SGMO: 8 Credits, SGH-SSH: 8 Credits, SSI: 5 Credits

## Sponsors



**Universitätsspital Basel**  
Innovations-Focus Zelltherapien  
Petersgraben 4  
4031 Basel  
[zelltherapien@usb.ch](mailto:zelltherapien@usb.ch)  
[unispital-basel.ch](https://unispital-basel.ch)

SED - 10.23



# Basel Cell Therapy Symposium November 9<sup>th</sup> 2023

organized by Innovation Focus Cell Therapies

## Program and registration



## Dear colleagues

We are very pleased to invite you to the 1<sup>st</sup> Basel Cell Therapy Symposium taking place on November 9th, 2023. This one-day meeting aims to discuss current clinical applications and research advances in cell-based therapies. Our ambition is to highlight the innovative promises driven by cell therapies to the broad and diverse scientific community in Switzerland and to promote synergies between academic, clinical and industrial partners.

We look forward to your attendance and contribution to this meeting.

The Innovation Focus Cell Therapies Team

## Program Basel Cell Therapy Symposium 2023

|  |  |
|--|--|
| 7.45   | <b>Registration</b>  |
| 8.10–8.20  | <b>Welcome and opening – Innovation Focus Cell Therapies</b>   |
| <b>Keynote Lecture 1</b><br>chaired by Heinz Läubli (University Hospital Basel, Switzerland)   |  |
| 8.20–9.05  | <b>John Haanen</b> «Understanding TIL therapy for the treatment of metastatic melanoma»  |
| <b>Session 1: «Non-engineered lymphocytes»</b><br>chaired by Nina Khanna (University Hospital Basel, Switzerland)  |  |
| 9.05–9.10  | Introduction to the session  |
| 9.10–9.35  | <b>Alexandre Harari</b> «Clonotypes dynamics during adoptive cell transfer in cancer patients»   |
| 9.35–10.00   | <b>Patrizia Comoli</b> «Update on multivirus-specific T cell therapies»  |
| 10.00–10.25  | <b>Mohammed Javeed Ansari</b> «Virus-specific T cell Therapy for Treatment of BK virus infection in Kidney Transplant Recipients»  |
| 10.25–10.35  | <b>David König</b> (University Hospital Basel): «Adoptive cell therapy with tumor-infiltrating lymphocytes and ANV419. Interim results of the phase I BaseTIL-03M trial» |
| 10.35–10.45  | <b>Dennis Strobbe</b> (University of Basel and University Hospital Basel): «Profiling of Epstein-Barr Virus-Specific T Cells in TSCM-enriched Immune Therapy»            |
| 10.45–11.15  | <b>Coffee Break and Poster Session</b>   |
| <b>Keynote Lecture 2</b><br>chaired by Lukas Jeker (University Hospital Basel, University of Basel, Switzerland)   |  |
| 11.15–12.00  | <b>Waseem Qasim</b> «Genome edited allo-CAR T trials»  |
| 12.00–14.00  | <b>Lunch and Poster Session</b>  |
| <b>Session 2: «Engineered lymphocytes»</b><br>chaired by Andreas Holbro (University Hospital Basel, Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland) |  |
| 14.00–14.05  | Introduction to the session  |
| 14.05–14.30  | <b>Maria Themeli</b> «Next generation of CAR T cells: combining targets, costimulation and logic gating»   |

|  |  |
|--|--|
| 14.30–14.55  | <b>Michael Hudecek</b> «Novel targets and technologies for CAR T cells»  |
| 14.55–15.20  | <b>Melita Irving</b> «Coengineering safety and function into T cells for cancer immunotherapy»   |
| 15.20–15.30  | <b>Gregor Hutter</b> (University Hospital Basel): «Enhancing glioblastoma clearance: Empowering anti-EGFRvIII CAR T cells with a paracrine SIRPY-derived CD47 blocker» |
| 15.30–15.40  | <b>Raphaël Porret</b> (University of Lausanne): «Redirecting TCR specificity in regulatory T cells toward class I HLA-restricted islet antigens»                       |
| 15.40–16.10  | <b>Coffee Break and Poster Session</b>   |
| <b>Session 3: «Engineered stem cells and access to therapy»</b><br>chaired by Jakob Passweg (University Hospital Basel, Switzerland) |  |
| 16.10–16.15  | Introduction to the session  |
| 16.15–16.40  | <b>Selim Corbacioglu</b> «Curative treatment options for sickle cell disease and transfusion-dependent thalassemia»  |
| 16.40–17.05  | <b>Lukas Jeker</b> «Molecular Cell Shielding - A Therapeutic Platform Approach for Hematologic Diseases»   |
| 17.05–17.30  | <b>Claire Booth</b> «Access to gene therapy for rare diseases»   |
| 17.30–17.40  | <b>Astrid Beerlage</b> (University of Basel and University Hospital Basel): «Base Edited HSPCs are Shielded from Targeted CD33 Therapy but Preserve CD33 Expression»   |
| 17.40–17.50  | <b>Amiq Gazdhar</b> (University Hospital Bern): «Secretome of Induced pluripotent stem cells for lung repair and regeneration»   |
| 17.50–17.55  | <b>Closing remark</b>  |

## Invited Speakers

**Mohammed Javeed Ansari**, Associate Professor of Medicine, Divisions of Nephrology and Organ Transplantation, Translational and Clinical Researcher in Transplantation Immunobiology, Northwestern University Feinberg School of Medicine, Chicago, USA.

**Claire Booth**, Professor in Gene Therapy and Paediatric Immunology, Senior Clinical Lecturer in Gene Therapy, Consultant Paediatric Immunologist, UCL Great Ormond Street Institute of Child Health, London, UK, Visiting Lecturer, Boston Children's Hospital/ Dana Farber Cancer Institute, (Pediatric Hematology/Oncology), Boston, MA, USA

**Patrizia Comoli**, Director of the Cell Factory and Center for Advanced Therapies and Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Assistant Professor in General Paediatrics, Bachelor of Medicine, University of Pavia, Italy

**Selim Corbacioglu**, Professor of Pediatrics, Chair of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Children's Hospital Regensburg, the University of Regensburg, Germany

**John Haanen**, Scientific Group Leader, Division of Molecular Oncology and Immunology, CSO Immunotherapy, Director of the Center for Cellular Therapy, The Netherlands Cancer Institute (NKI), Amsterdam, Netherlands, Professor of Translational Immunotherapy, Cancer at Leiden University Medical Center, Leiden, Netherlands, Consultant Medical Oncologist

**Alexandre Harari**, Associate Professor, Research Group Leader, Human integrated tumor immunology discovery engine (Hi-TiDe), University of Lausanne, Lausanne University Hospital, Ludwig Institute for Cancer Research Lausanne, Switzerland

**Michael Hudecek**, Professor of Cellular Immunotherapy for Malignant Diseases, University Hospital Würzburg, Germany, Research group leader, Internal Medicine/Hematology, University of Würzburg, Germany

**Melita Irving**, Group Leader, Ludwig Institute for Cancer Research, Lausanne Department of Oncology, University of Lausanne, Switzerland

**Lukas Jeker**, Assistant Professor of Experimental Transplantation Immunology & Nephrology, University Hospital Basel, Switzerland, Research Group Leader, Department of Biomedicine, University Hospital Basel, University of Basel, Switzerland

**Waseem Qasim**, Professor of Cell and Gene Therapy, NIHR Senior Investigator, UCL Great Ormond Street Institute of Child Health, London, Consultant in Paediatric Immunology, Great Ormond Street Hospital

**Maria Themeli**, Assistant Professor, CCA - Cancer Biology and Immunology, Assistant Professor, Hematology laboratory, Cancer Center Amsterdam, Amsterdam University Medical Centers, VUmc, The Netherlands